US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ATYR PHARMA INC

3.30

-0.2800-7.82%

Volume:476.77K

Turnover:1.62M

Market Cap:293.23M

PE:-3.83

High:3.57

Open:3.53

Low:3.29

Close:3.58

Loading ...

Overview Company News Filings

When Will aTyr Pharma, Inc. (NASDAQ:ATYR) Turn A Profit?

Simply Wall St.

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

US High Growth Tech Stocks to Watch in 2023

Simply Wall St.

aTyr Pharma to Participate in April Investor Conferences

Piper Sandler Remains a Buy on aTyr Pharma (ATYR)

BRIEF-ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

BRIEF-aTyr Pharma Announces The Appointment Of Dalia R. Rayes As Head Of Commercial, Global Efzofitimod Franchise

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

THOMSON REUTERS

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (RCUS), aTyr Pharma (ATYR) and Lyra Therapeutics (LYRA)

aTyr Pharma Price Target Maintained With a $35.00/Share by HC Wainwright & Co.

aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ...

aTyr Pharma Q4 EPS $(0.18) Beats $(0.23) Estimate

Press Release: aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

aTyr Pharma Inc expected to post a loss of 23 cents a share - Earnings Preview

aTyr Pharma Announces Fourth Positive Dsmb Review for Efzofitimod in Phase 3 Efzo-Fit™ Study in Pulmonary Sarcoidosis

THOMSON REUTERS

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

aTyr Pharma Initiated at Outperform by Leerink Partners

Leerink Partners Initiates Coverage on aTyr Pharma With Outperform Rating, $16 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ATYR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATYR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATYR\",,,,,undefined,":{"symbol":"ATYR","market":"US","secType":"STK","nameCN":"ATYR PHARMA INC","latestPrice":3.3,"timestamp":1746550105860,"preClose":3.58,"halted":0,"volume":476766,"delay":0,"floatShares":81953560,"shares":88858612,"eps":-0.862131,"marketStatus":"Trading","change":-0.28,"latestTime":"05-06 12:48:27 EDT","open":3.53,"high":3.57,"low":3.29,"amount":1616550.7380876,"amplitude":0.078212,"askPrice":3.31,"askSize":400,"bidPrice":3.3,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.862131,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746561600000},"marketStatusCode":2,"adr":0,"listingDate":1430971200000,"exchange":"NASDAQ","adjPreClose":3.58,"preHourTrading":{"tag":"盘前","latestPrice":3.6781,"preClose":3.58,"latestTime":"09:12 EDT","volume":116,"amount":424.6443088,"timestamp":1746537165408},"postHourTrading":{"tag":"盘后","latestPrice":3.58,"preClose":3.58,"latestTime":"19:54 EDT","volume":1519,"amount":5442.75,"timestamp":1746489266812},"volumeRatio":0.944123,"impliedVol":1.486,"impliedVolPercentile":0.5304},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATYR\",,,,,undefined,":{"symbol":"ATYR","floatShares":81953560,"roa":"-39.03%","roe":"-79.88%","lyrEps":-0.862131,"volumeRatio":0.944123,"shares":88858612,"dividePrice":0,"high":3.57,"amplitude":0.078212,"preClose":3.58,"low":3.29,"week52Low":1.42,"pbRate":"4.19","psRate":"1247.80","week52High":4.66,"institutionHeld":0,"latestPrice":3.3,"committee":-0.333333,"eps":-0.862131,"divideRate":0,"volume":476766,"delay":0,"ttmEps":-0.862131,"open":3.53,"prevYearClose":3.62,"prevWeekClose":3.6,"prevMonthClose":3.47,"prevQuarterClose":3.02,"fiveDayClose":3.38,"twentyDayClose":2.85,"sixtyDayClose":3.9},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATYR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531479930","title":"When Will aTyr Pharma, Inc. (NASDAQ:ATYR) Turn A Profit?","url":"https://stock-news.laohu8.com/highlight/detail?id=2531479930","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531479930?lang=en_us&edition=fundamental","pubTime":"2025-04-30 02:33","pubTimestamp":1745951601,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse aTyr Pharma, Inc.'s  business as it appears the company may be on the cusp of a considerable accomplishment. aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. On 31 December 2024, the US$298m market-cap company posted a loss of US$64m for its most recent financial year. As path to profitability is the topic on aTyr Pharma's investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atyr-pharma-inc-nasdaq-atyr-183321148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210149790.SGD","BK4139","SQQQ","NDAQ",".IXIC","TQQQ","BK4588","QID","BK4585","USAW.SI","IE00B64PRP62.GBP","NVIW.SI","USJW.SI","QLD","MNQmain","IE00BKPKM429.USD","TSYW.SI","ATYR","LU2095319765.USD","PSQ","NQmain","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2531733329","title":"aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531733329","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531733329?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:00","pubTimestamp":1745928000,"startTime":"0","endTime":"0","summary":"Findings demonstrate ATYR2810’s anti-tumor activity and increased survival in a model of glioblastoma multiforme , a primary form of brain cancer.The poster presents preclinical research evaluating the use of ATYR2810 in syngeneic tumor models including the orthotopic CT-2A mouse model of GBM, which has a high prevalence of myeloid-derived suppressor cells that exhibit enriched expression of NRP2 and promote an immunosuppressive tumor microenvironment. The findings demonstrate that ATYR2810 when used as a single agent enhanced anti-tumor immunity and resulted in a significant increase in overall survival. Additionally, when combined with an anti-PD-1 agent, ATYR2810 further increased survival and reduced tumor size. These findings suggest that modulating NRP2 may offer a new approach to reversing the immunosuppressive function of myeloid cells in the tumor microenvironment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atyr-pharma-presents-preclinical-data-120000528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4117","ATYR","BK4107","AFG","BK4139"],"gpt_icon":0},{"id":"2526687763","title":"US High Growth Tech Stocks to Watch in 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2526687763","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526687763?lang=en_us&edition=fundamental","pubTime":"2025-04-09 19:38","pubTimestamp":1744198696,"startTime":"0","endTime":"0","summary":"As the U.S. market experiences heightened volatility with major indices like the S&P 500 and Nasdaq Composite closing sharply lower amid tariff concerns, investors are closely monitoring economic indicators that could impact small-cap companies and technology stocks. In such a climate, identifying high-growth tech stocks involves looking for companies that demonstrate resilience through innovation and adaptability to shifting trade policies, making them noteworthy in this unpredictable environment.Top 10 High Growth Tech Companies In The United States. Akebia Therapeutics, despite its unprofitable status, is poised for significant growth with expected annual revenue increases of 27.2% outpacing the U.S. market's 8.2%. This biotech firm is navigating towards profitability within three years, bolstered by a robust pipeline evidenced by recent positive CHMP opinions on XOANACYL for CKD-related conditions. However, financial challenges remain as highlighted by a $69.41 million net loss in ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/us-high-growth-tech-stocks-113816581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","AKBA","MGTX","ATYR"],"gpt_icon":1},{"id":"2524259876","title":"aTyr Pharma to Participate in April Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2524259876","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524259876?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:00","pubTimestamp":1743681600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 03, 2025  -- aTyr Pharma, Inc. , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2025.Conference: Jones Healthcare and Technology Innovation Conference Date: April 8 – 9, 2025Location: Las Vegas, NVFormat: 1x1 Investor Meetings. For more information on how to register, please contact your Jones or Piper Sandler representative.Contact:Ashlee DunstonSr. Director, Investor Relations and Public Affairsadunston@atyrpharma.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atyr-pharma-participate-april-investor-120000827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATYR","BK4139"],"gpt_icon":1},{"id":"2523977917","title":"Piper Sandler Remains a Buy on aTyr Pharma (ATYR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2523977917","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523977917?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:56","pubTimestamp":1743418595,"startTime":"0","endTime":"0","summary":"In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on aTyr Pharma (ATYR – Research Report), with a price target ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-atyr-pharma-atyr-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-atyr-pharma-atyr-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2522553939","title":"BRIEF-ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522553939","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522553939?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:00","pubTimestamp":1743105643,"startTime":"0","endTime":"0","summary":"BRIEF-ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)March 27 (Reuters) - aTyr Pharma Inc ATYR.O:ATYR PHARMA ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nGNX24vnkbFurther company coverage: ATYR.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA5W1Q5Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2522539363","title":"aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539363","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539363?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:00","pubTimestamp":1743105600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA5W1Q5Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2522687425","title":"BRIEF-aTyr Pharma Announces The Appointment Of Dalia R. Rayes As Head Of Commercial, Global Efzofitimod Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2522687425","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522687425?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:07","pubTimestamp":1742990835,"startTime":"0","endTime":"0","summary":"BRIEF-aTyr Pharma Announces The Appointment Of Dalia R. Rayes As Head Of Commercial, Global Efzofitimod FranchiseMarch 26  - aTyr Pharma Inc ATYR.O:ATYR PHARMA ANNOUNCES THE APPOINTMENT OF DALIA R. RAYES AS HEAD OF COMMERCIAL, GLOBAL EFZOFITIMOD FRANCHISESource text: ID:nGNX59kDFurther company coverage: ATYR.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA1CV1J7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2522871717","title":"aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2522871717","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522871717?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:00","pubTimestamp":1742990403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA1CV1J7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2522889808","title":"aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2522889808","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522889808?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:00","pubTimestamp":1742990400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 26, 2025  -- aTyr Pharma, Inc.  , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise. Ms. Rayes brings over 25 years of experience building and leading commercial organizations at biotechnology and pharmaceutical companies, including leading rare disease product launches. She will serve as a member of the Company’s executive leadership team, overseeing global commercial strategy and operations for the efzofitimod program in interstitial lung disease , including its lead indication in pulmonary sarcoidosis.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atyr-pharma-announces-appointment-dalia-120000781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2519877861","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (RCUS), aTyr Pharma (ATYR) and Lyra Therapeutics (LYRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2519877861","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519877861?lang=en_us&edition=fundamental","pubTime":"2025-03-14 19:00","pubTimestamp":1741950059,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arcus Biosciences (RCUS – Research Report), aTyr P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-arcus-biosciences-rcus-atyr-pharma-atyr-and-lyra-therapeutics-lyra?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-arcus-biosciences-rcus-atyr-pharma-atyr-and-lyra-therapeutics-lyra?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LYRA","ATYR","BK4137","RCUS","BK4139","HCSG","BK4007"],"gpt_icon":0},{"id":"2519799872","title":"aTyr Pharma Price Target Maintained With a $35.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2519799872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519799872?lang=en_us&edition=fundamental","pubTime":"2025-03-14 18:59","pubTimestamp":1741949940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATYR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 14, 2025 06:59 ET (10:59 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR"],"gpt_icon":0},{"id":"2519427168","title":"aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2519427168","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519427168?lang=en_us&edition=fundamental","pubTime":"2025-03-14 15:11","pubTimestamp":1741936271,"startTime":"0","endTime":"0","summary":"Cash and Investments: $75.1 million at the end of 2024.ATM Offering Proceeds: Approximately $18.8 million raised subsequent to Q4 2024.Collaboration and License Revenue: $0.2 million for 2024 from the Kurin Agreement.Total Revenue from Kurin Agreement: Over $20 million received to date, with potential for up to $155 million in additional milestone payments.Research and Development Expenses: $54.4 million for the year ended 2024.General and Administrative Expenses: $13.8 million for the year ended 2024.Cash Runway: Expected to fund operations through one year following the phase 3 FSOfi readout.GuruFocus has detected 5 Warning Signs with ATYR.For the complete transcript of the earnings call, please refer to the full earnings call transcript.aTyr Pharma Inc  has published a manuscript in Science Translational Medicine, validating the mechanism of action of epsofitamo and reinforcing its potential application in chronic inflammatory conditions.The company has a strong cash position, endin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atyr-pharma-inc-atyr-q4-071111439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATYR"],"gpt_icon":0},{"id":"2519699958","title":"aTyr Pharma Q4 EPS $(0.18) Beats $(0.23) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2519699958","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519699958?lang=en_us&edition=fundamental","pubTime":"2025-03-14 04:11","pubTimestamp":1741896669,"startTime":"0","endTime":"0","summary":"aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 28 percent increase over losses of $(0.25) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44315888/atyr-pharma-q4-eps-0-18-beats-0-23-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"aTyr Pharma Q4 EPS $(0.18) Beats $(0.23) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR"],"gpt_icon":0},{"id":"2519866726","title":"Press Release: aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519866726","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519866726?lang=en_us&edition=fundamental","pubTime":"2025-03-14 04:01","pubTimestamp":1741896060,"startTime":"0","endTime":"0","summary":"Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces its favorable safety profile.\"2024 was an important year for aTyr, as we completed enrollment in our global pivotal Phase 3 EFZO-FIT study, which is the largest interventional study ever to be conducted in pulmonary sarcoidosis, a disease where incidence and prevalence are rising yet there are still limited treatment options,\" said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. \"The stage is set for 2025 to be a potential milestone year as we look toward reporting topline data for EFZO-FIT in the third quarter. Leading into this pivotal readout, we are very pleased with the execution of the study to date and the continued favorable safety profile demonstrated for efzofitimod, including our most recent positive DSMB review, which recommended the study continue ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BK4588","BK4613","BK4099","ATYR","BK4604","BK4555","03160","BK4585","BK4139","BK4023","TM","SAP","ATS","BK4528"],"gpt_icon":1},{"id":"2518719987","title":"aTyr Pharma Inc  expected to post a loss of 23 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2518719987","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518719987?lang=en_us&edition=fundamental","pubTime":"2025-03-12 04:09","pubTimestamp":1741723746,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc  expected to post a loss of23cents a share - Earnings Preview aTyr Pharma Inc ATYR.OQ ATYR.O is expected to show a rise in quarterly revenue when it reports  results on March 13 for th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nL8N3PU28I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR"],"gpt_icon":0},{"id":"2517612118","title":"aTyr Pharma Announces Fourth Positive Dsmb Review for Efzofitimod in Phase 3 Efzo-Fit™ Study in Pulmonary Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2517612118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517612118?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:02","pubTimestamp":1741294946,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PP1KU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2516493676","title":"aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516493676","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516493676?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093200,"startTime":"0","endTime":"0","summary":"Management to host conference call and webcast on March 13th at 5:00 pm EDT / 2:00 pm PDT. SAN DIEGO, March 04, 2025  -- aTyr Pharma, Inc. , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2024 financial results and provide a corporate update after the market close on Thursday, March 13, 2025. Management will host a conference call and webcast to review the results and provide an operational update.Participants who wish to join the conference call by telephone must register at the above dial-in registration link in order to receive the dial-in number and a personalized PIN code that will be required to access the call. Participants may join the live webcast by accessing it at the above webcast registration link on the aTyr Events page. For more information or questions, please contact aTyr’s investor relations team a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atyr-pharma-webcast-conference-call-130000373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATYR","BK4139"],"gpt_icon":1},{"id":"2512592671","title":"aTyr Pharma Initiated at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2512592671","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512592671?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:13","pubTimestamp":1739880780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATYR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2025 07:13 ET (12:13 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR"],"gpt_icon":0},{"id":"2512815953","title":"Leerink Partners Initiates Coverage on aTyr Pharma With Outperform Rating, $16 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2512815953","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512815953?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:09","pubTimestamp":1739880547,"startTime":"0","endTime":"0","summary":"aTyr Pharma (ATYR) has an average rating of Buy and mean price target of $20, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATYR"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATYR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-13","symbol":"ATYR","fiscalQuarterEnding":"2024/12","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2024-11-07","symbol":"ATYR","fiscalQuarterEnding":"2024/09","expectedEps":-0.22,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.23},{"market":"US","date":"2024-08-13","symbol":"ATYR","fiscalQuarterEnding":"2024/06","expectedEps":-0.22,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":-0.23},{"market":"US","date":"2024-05-02","symbol":"ATYR","fiscalQuarterEnding":"2024/03","expectedEps":-0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1714622400000,"reportTimeType":"post","actualEps":-0.23},{"market":"US","date":"2024-03-14","symbol":"ATYR","fiscalQuarterEnding":"2023/12","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1710388800000,"reportTimeType":"post","actualEps":-0.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATYR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATYR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1818,"buy":0.8182,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8182,"analysts":11,"updateTime":1740196800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ATYR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ATYR","date":"2025-05-05","current":-4.996501,"percent":0.105769,"low":-5.827142,"twenty":-4.75379,"median":-4.097658,"eighty":-2.427591,"high":-1.932291,"avg":-3.741434,"sd":1.09267,"marketCap":319891003},"quantilePoints":[{"date":"2024-06-07","current":-2.380173,"twenty":-2.380173,"median":-2.380173,"eighty":-2.380173,"marketCap":128360348},{"date":"2024-06-14","current":-2.367376,"twenty":-2.482546,"median":-2.431359,"eighty":-2.377614,"marketCap":127670239},{"date":"2024-06-21","current":-2.021867,"twenty":-2.446715,"median":-2.367376,"eighty":-2.203579,"marketCap":109037285},{"date":"2024-06-28","current":-1.970681,"twenty":-2.431359,"median":-2.367376,"eighty":-2.111444,"marketCap":106276847},{"date":"2024-07-05","current":-1.970681,"twenty":-2.431359,"median":-2.265003,"eighty":-1.991155,"marketCap":106276847},{"date":"2024-07-12","current":-2.073054,"twenty":-2.39041,"median":-2.092249,"eighty":-1.970681,"marketCap":111797722},{"date":"2024-07-15","current":-2.226613,"twenty":-2.380173,"median":-2.111444,"eighty":-1.970681,"marketCap":120079035},{"date":"2024-08-02","current":-2.495343,"twenty":-2.421122,"median":-2.130639,"eighty":-1.9758,"marketCap":134571333},{"date":"2024-08-09","current":-2.380173,"twenty":-2.403207,"median":-2.265003,"eighty":-1.996274,"marketCap":128360348},{"date":"2024-08-16","current":-2.618312,"twenty":-2.418704,"median":-2.296995,"eighty":-2.001393,"marketCap":151592396},{"date":"2024-08-23","current":-2.448121,"twenty":-2.445503,"median":-2.341783,"eighty":-2.021867,"marketCap":141738890},{"date":"2024-08-30","current":-2.474305,"twenty":-2.468042,"median":-2.373775,"eighty":-2.032104,"marketCap":143254814},{"date":"2024-09-06","current":-2.291023,"twenty":-2.461213,"median":-2.354579,"eighty":-2.073054,"marketCap":132643346},{"date":"2024-09-13","current":-2.448121,"twenty":-2.474305,"median":-2.380173,"eighty":-2.111444,"marketCap":141738890},{"date":"2024-09-20","current":-2.448121,"twenty":-2.474305,"median":-2.399368,"eighty":-2.149834,"marketCap":141738890},{"date":"2024-09-27","current":-2.277931,"twenty":-2.474305,"median":-2.382664,"eighty":-2.226613,"marketCap":131885384},{"date":"2024-10-04","current":-2.277931,"twenty":-2.469749,"median":-2.373775,"eighty":-2.226613,"marketCap":131885384},{"date":"2024-10-11","current":-2.77541,"twenty":-2.474305,"median":-2.382664,"eighty":-2.251748,"marketCap":160687939},{"date":"2024-10-18","current":-3.469263,"twenty":-2.48085,"median":-2.399368,"eighty":-2.251748,"marketCap":200859924},{"date":"2024-10-25","current":-4.241665,"twenty":-2.500488,"median":-2.421938,"eighty":-2.265003,"marketCap":245579681},{"date":"2024-10-31","current":-4.097658,"twenty":-2.555472,"median":-2.431359,"eighty":-2.275241,"marketCap":237242099},{"date":"2024-11-08","current":-4.058383,"twenty":-2.922036,"median":-2.441575,"eighty":-2.277905,"marketCap":234968213},{"date":"2024-11-15","current":-3.78886,"twenty":-3.621287,"median":-2.448121,"eighty":-2.277931,"marketCap":241789871},{"date":"2024-11-22","current":-3.919838,"twenty":-3.629704,"median":-2.448121,"eighty":-2.277931,"marketCap":250148372},{"date":"2024-11-29","current":-4.643298,"twenty":-3.916561,"median":-2.461213,"eighty":-2.285786,"marketCap":296316696},{"date":"2024-12-06","current":-4.301299,"twenty":-4.007344,"median":-2.474305,"eighty":-2.298878,"marketCap":274491670},{"date":"2024-12-13","current":-3.972453,"twenty":-4.100191,"median":-2.474305,"eighty":-2.31136,"marketCap":253506069},{"date":"2024-12-20","current":-4.143453,"twenty":-4.111931,"median":-2.474305,"eighty":-2.3168,"marketCap":264418582},{"date":"2024-12-27","current":-4.95899,"twenty":-4.144489,"median":-2.487396,"eighty":-2.317206,"marketCap":316462874},{"date":"2025-01-03","current":-5.143143,"twenty":-4.229494,"median":-2.500488,"eighty":-2.317206,"marketCap":328214811},{"date":"2025-01-10","current":-4.919528,"twenty":-4.267848,"median":-2.526671,"eighty":-2.317206,"marketCap":313944602},{"date":"2025-01-17","current":-4.932682,"twenty":-4.327606,"median":-2.579037,"eighty":-2.328986,"marketCap":314784026},{"date":"2025-01-24","current":-4.682759,"twenty":-4.341161,"median":-2.768865,"eighty":-2.330035,"marketCap":298834968},{"date":"2025-01-31","current":-4.919528,"twenty":-4.389843,"median":-2.932509,"eighty":-2.330297,"marketCap":313944602},{"date":"2025-02-07","current":-5.090528,"twenty":-4.509129,"median":-3.510289,"eighty":-2.339486,"marketCap":324857115},{"date":"2025-02-14","current":-4.722221,"twenty":-4.606467,"median":-3.575068,"eighty":-2.341783,"marketCap":301353241},{"date":"2025-02-21","current":-5.827142,"twenty":-4.643298,"median":-3.6107,"eighty":-2.357139,"marketCap":371864863},{"date":"2025-02-28","current":-5.090528,"twenty":-4.682759,"median":-3.851618,"eighty":-2.375054,"marketCap":324857115},{"date":"2025-03-07","current":-4.051376,"twenty":-4.682759,"median":-3.972453,"eighty":-2.380173,"marketCap":258542613},{"date":"2025-03-14","current":-5.248373,"twenty":-4.682759,"median":-3.985607,"eighty":-2.381668,"marketCap":334930203},{"date":"2025-03-21","current":-4.929845,"twenty":-4.727483,"median":-3.990774,"eighty":-2.382664,"marketCap":315623450},{"date":"2025-03-28","current":-4.52461,"twenty":-4.75379,"median":-4.035211,"eighty":-2.388848,"marketCap":289679075},{"date":"2025-04-04","current":-3.872289,"twenty":-4.740636,"median":-4.038222,"eighty":-2.400648,"marketCap":247915527},{"date":"2025-04-11","current":-3.802893,"twenty":-4.727483,"median":-4.011134,"eighty":-2.407615,"marketCap":243472596},{"date":"2025-04-17","current":-4.191509,"twenty":-4.722221,"median":-4.035211,"eighty":-2.414083,"marketCap":268353008},{"date":"2025-04-25","current":-4.788314,"twenty":-4.743267,"median":-4.051376,"eighty":-2.421938,"marketCap":306562211},{"date":"2025-05-02","current":-4.635643,"twenty":-4.743267,"median":-4.087671,"eighty":-2.425706,"marketCap":296787764},{"date":"2025-05-05","current":-4.996501,"twenty":-4.75379,"median":-4.097658,"eighty":-2.427591,"marketCap":319891003}],"updateTime":1746531429687}}}